SecBot SecBot

PTCT drug pipeline

PTC THERAPEUTICS, INC. · 9 rated drugs
$60.97
−4.0% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±6.6%
1-day, median of 2 events
IV rank
34
IV 50% · HV 53%
Rated drugs
9
2 bullish · 3 bearish · 4 neutral
Phase 3 trials
4
3 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhaseFiled/BLA-stage (Phase 1/2 registrational study completed)
Time to marketPotential FDA accelerated approval and commercial launch in 2027 if the BLA submission is completed in Q4 2026 and the FDA grants a standard or priority review timeline.

ST-920 isaralgagene civaparvovec Updated Oct 30

What to watch

Watch for completion of the rolling BLA submission to the FDA in Q4 2026 (by Dec 31). If submitted on time, the FDA will set a PDUFA date, likely in H2 2027, which would be the next major binary catalyst. Any delay in the BLA submission would be a negative signal. Also monitor the WORLD Symposium in February 2027 for updated clinical data.

Bull case
  • ST-920 is a one-time gene therapy that could replace lifelong biweekly enzyme replacement infusions for Fabry disease, a clear value proposition for patients and payers.
  • The Phase 1/2 STAAR study showed a positive mean annualized eGFR slope of +1.965 at 52 weeks, indicating renal function improvement, and the FDA agreed this can serve as the primary basis for accelerated approval.
  • The therapy requires no preconditioning (no chemotherapy), simplifying administration versus some other gene therapies.
Bear case
  • The BLA submission is based on a single-arm Phase 1/2 study (STAAR) with 32-36 patients, not a randomized controlled trial, which raises regulatory risk for full approval.
  • The 95% confidence interval for the eGFR slope (-0.153 to 4.083) crosses zero, meaning the result was not statistically significant at conventional levels.
  • Competing gene therapies from 4D Molecular Therapeutics (4D-310) and Freeline are also in development, and established ERT products (Fabrazyme, Replagal) and oral chaperone Galafold already serve the market.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since August 2020.

Evrysdi risdiplam Updated Oct 30

What to watch

Evrysdi is a mature, approved drug with no upcoming binary catalysts. PTC has already monetized virtually all of its royalty interest. Investors should watch PTC's Q4 2026 earnings (likely late January/early February 2027) for Evrysdi full-year sales trends and whether the $2.5B annual sales milestone for the $150M Roche payment is approaching, but the stock's primary catalysts now lie elsewhere in PTC's pipeline.

Bull case
  • Evrysdi is the fastest-growing SMA therapy, driven by oral convenience and broad age eligibility, with year-to-date sales through Q3 2026 of approximately CHF 1,470 million (roughly $1.7B), up ~30% year-over-year.
  • PTC retains a $150 million milestone payment from Roche if Evrysdi achieves single-year sales of $2.5 billion, providing upside optionality.
  • The drug continues to gain label expansions (tablet formulation Feb 2025, feeding tube administration Feb 2026), expanding the addressable patient population.
Bear case
  • PTC has fully monetized its Evrysdi royalty stream, selling 100% of the royalty interest to Royalty Pharma by December 2025 for a total of approximately $1.9B across multiple transactions. The remaining royalty revenue PTC reports is a diminishing pass-through.
  • Evrysdi faces competition from Biogen's Spinraza (intrathecal injection) and Novartis' Zolgensma (one-time gene therapy), plus emerging pipeline therapies like Scholar Rock's apitegromab.
  • PTC's stock is now driven by other assets (Sephience for PKU, ST-920 for Fabry disease), making Evrysdi a less central part of the investment thesis.
▲ bullish
Impact
PhaseApproved
Time to marketAlready approved and commercially available in the US (since July 2025) and EU (since June 2025). International expansion into Japan and Brazil is ongoing.

Sephience sepiapterin Updated Oct 30

What to watch

Sephience is already approved and generating significant revenue, so the next catalysts are commercial: watch quarterly revenue growth, patient starts, and market share data versus BioMarin's Kuvan and Palynziq. International approval decisions in Japan and Brazil could provide upside, though no specific dates are set. The stock's 29% discount to its 52-week high and 51.7% implied upside to the analyst mean target suggest the market may be underappreciating the launch trajectory, but persistent insider selling and mixed institutional flows warrant monitoring.

Bull case
  • Sephience generated $182M in Q3 2026 revenue, driving the company to raise full-year product revenue guidance to $960M-$990M, suggesting rapid commercial uptake and strong demand.
  • Clinical data showed a 63% reduction in blood phenylalanine versus placebo, and real-world evidence demonstrates a 76% response rate including patients who did not respond to older therapies like Kuvan.
  • The drug has broad labeling covering patients from 1 month of age and older, giving it a wide addressable market across the full PKU severity spectrum.
Bear case
  • The stock trades 29% below its 52-week high of $90.87, and the bearish net signal from the bull/bear checklist reflects persistent insider selling (director Michael Schmertzler alone sold over $1M in shares in recent months, all under 10b5-1 plans).
  • Competition from BioMarin's established PKU drugs Kuvan (sapropterin, available as generic) and Palynziq (pegvaliase) could limit market share gains, and some patients may not respond to sepiapterin.
  • Analysts on the Q3 earnings call raised questions about US growth sustainability, seasonality, and conversion from switches, suggesting the rapid launch trajectory may face headwinds.
▼ bearish
Impact
PhaseApproved
Time to marketAlready on the market since 2017.

Emflaza deflazacort Updated Oct 30

What to watch

Emflaza is a post-exclusivity asset in revenue decline with no upcoming binary catalyst. The key event to watch for this drug is the pace of revenue erosion in PTC's quarterly earnings reports, as generic competition continues to erode market share. For PTC Therapeutics overall, the focus has shifted to Sephience's commercial trajectory and the ST-920 Fabry gene therapy BLA submission expected in Q4 2026.

Bull case
  • Emflaza remains the only FDA-approved corticosteroid specifically indicated for DMD, and brand loyalty and patient-support services (PTC Cares) have helped sustain some revenue despite generic entry, with $25.1M in Q3 2026.
  • PTC Therapeutics as a whole is growing rapidly (Q3 2026 total revenue of $358M, up ~70% YoY), and Emflaza's decline is more than offset by Sephience's $182M quarterly launch, so the drug's erosion does not threaten the company.
  • Analyst consensus on PTCT is bullish (17 buy/strong-buy vs 2 hold and 1 sell out of 20 analysts), with a mean price target of $97.81 implying ~52% upside from the $64.46 close.
Bear case
  • Generic competition is entrenched: Aurobindo launched generic deflazacort tablets in February 2024, and Tris Pharma (Cranbury) received FDA approval for a generic oral suspension. Multiple generic suppliers now compete on price.
  • The last FDA exclusivity (orphan drug exclusivity for ages 2-5) expired in June 2026, removing the final barrier to full generic competition across all age groups.
  • Emflaza revenue is in structural decline: Q3 2026 net product revenue of $25.1M was down 29% from $35.2M in Q3 2025, and Q2 2026 revenue of $24.6M was down 32% from $36.4M in Q2 2025.
● neutral
Impact
PhasePhase 2a
Time to marketAt least 5-7 years away, if successful. The drug is in early Phase 2a (not yet recruiting), with no Phase 3 trials designed or regulatory filings planned. Even after positive Phase 2a data, the drug would need larger Phase 3 trials and FDA review before any potential approval.

PTC844 Updated Oct 30

What to watch

PTC844 has no hard binary catalyst in the next 12 months. The Phase 2a trial is not yet recruiting; watch for the first patient dosed and eventual topline data (estimated primary completion September 2027). For PTCT investors, the stock's near-term drivers are Sephience sales growth, the ST-920 Fabry gene therapy BLA submission (expected Q4 2026), and the votoplam Type C FDA meeting (Q1 2027), not PTC844.

Bull case
  • PTC844 demonstrated ~16,000-fold selectivity for DHODH over off-target enzymes vs ~9-fold for teriflunomide, suggesting a potentially much cleaner safety profile than existing DHODH inhibitors
  • In preclinical models, PTC844 reduced knee swelling by 60% (similar to methotrexate) in a rabbit arthritis model and outperformed cyclosporine, JAK inhibitors, and prednisolone in a xGvHD mouse model
  • PTC Therapeutics has a strong balance sheet ($2.13B cash) and commercial infrastructure to fund development without near-term financing risk
Bear case
  • PTC844 is very early-stage (Phase 2a not yet recruiting) with no human efficacy data; preclinical results often fail to translate to patients
  • The RA treatment landscape is crowded with many effective biologics, JAK inhibitors, and existing DHODH inhibitors (leflunomide); a new entrant needs clear differentiation
  • PTC844 represents a tiny fraction of PTCT's enterprise value; even positive Phase 2a data would have limited stock impact given the company's approved products and $5.2B market cap
▼ bearish
Impact
PhaseApproved (select countries)
Time to marketAlready approved in select countries (UK, Brazil, Israel, Russia, and others) since 2014; never approved in the US; EU authorization not renewed as of March 2025.

Translarna ataluren Updated Oct 30

What to watch

Translarna has no upcoming regulatory catalysts: the US NDA was withdrawn in February 2026 and the EU conditional authorization was not renewed in March 2025. The drug's revenue is declining ($48.5M in Q3 2026, down from $50.7M a year earlier) and PTC Therapeutics has pivoted to Sephience as its primary growth driver. Watch for further erosion of Translarna's international approvals and whether any individual EU countries maintain access via national provisions.

Bull case
  • Translarna remains approved in several countries outside the EU, including the UK (via MHRA conditional license), Brazil, Israel, and Russia, providing a continuing revenue stream.
  • Individual EU countries can still allow Translarna use via Articles 117(3) and 5(1) of EU Directive 2001/83, potentially preserving some European access.
  • The drug still generated $48.5M in Q3 2026 revenue with minimal ongoing R&D investment, contributing cash flow as PTC Therapeutics shifts focus to its growth assets Sephience and ST-920.
Bear case
  • FDA approval path is dead: PTC withdrew the NDA resubmission in February 2026 after the FDA said data were unlikely to meet the threshold of substantial evidence of effectiveness, closing off the US market permanently.
  • EU conditional marketing authorization was not renewed by the European Commission in March 2025 after the EMA concluded effectiveness had not been established, removing the drug from the European Economic Area.
  • Revenue is declining: Translarna generated $48.5M in Q3 2026, down from $50.7M in Q3 2025, and the company noted the quarter included a government purchase order from Russia, suggesting underlying demand is weakening.
▼ bearish
Impact
PhasePhase 3
Time to marketAt least 3-4 years away, if ever. PROVE-FA has a 24-month primary endpoint and began enrolling in Q3 2026, so topline data would not be available before late 2028, followed by NDA resubmission and FDA review.

vatiquinone Updated Oct 30

What to watch

The next catalyst is the PROVE-FA open-label Phase 3 study (initiated Q3 2026), which will enroll ~120 FA patients aged 7-21 and compare against matched natural history controls over 24 months. A positive readout could support NDA resubmission, but the open-label design may not satisfy the FDA's request for an "adequate and well-controlled study." No topline data is expected before late 2028 at the earliest, so vatiquinone is unlikely to be a near-term stock driver for PTCT.

Bull case
  • Long-term open-label data showed a 4.8-point benefit on mFARS versus a matched natural history population (p<0.0001, N=41), suggesting possible disease-modifying activity.
  • PROVE-FA, initiated in Q3 2026, is designed specifically to address FDA feedback and could support NDA resubmission if positive.
  • High unmet need exists: no FDA-approved therapy for pediatric Friedreich's ataxia patients, and vatiquinone has Orphan Drug and Fast Track designations.
Bear case
  • The MOVE-FA Phase 2/3 trial failed its primary endpoint (change in mFARS at 72 weeks), and the FDA's August 2025 CRL stated that substantial evidence of efficacy was not demonstrated.
  • The FDA specifically requested an 'additional adequate and well-controlled study,' but PROVE-FA is an open-label single-arm trial with natural history controls, which may not satisfy that requirement.
  • Even if PROVE-FA succeeds, NDA resubmission and potential approval are years away (the study has a 24-month primary endpoint), with no near-term binary catalyst.
● neutral
Impact
PhasePreclinical
Time to marketPTC303 has not yet entered human trials. Assuming a Phase 1 start in 2027 and a typical clinical development timeline for a rare neurological disease, potential approval would be many years away, likely in the 2030s if successful.

PTC303 Updated Oct 30

What to watch

PTC303 has no hard dated catalyst in the next 12 months. The next milestone to watch is the initiation of a Phase 1 clinical trial, which the company expects in 2027 (no specific quarter given). Given PTC303's preclinical stage and PTC Therapeutics' diversified pipeline with multiple approved products, this program is unlikely to drive meaningful share-price movement in the near term. Investors should monitor the Q4 2026 earnings call or corporate updates for a more specific timeline on Phase 1 initiation.

Bull case
  • MSH3 is a genetically validated target for Huntington's disease, supported by human genetic data linking MSH3 variation to disease severity and onset age.
  • PTC Therapeutics has deep expertise in splicing modulation, having successfully developed and commercialized other splicing-targeting drugs.
  • The approach is complementary to HTT-lowering strategies, potentially allowing combination therapy that addresses both the root cause and the somatic expansion driver of Huntington's disease.
Bear case
  • PTC303 is still preclinical with no human safety or efficacy data; most preclinical drug candidates fail before reaching the market.
  • The Phase 1 start is only broadly targeted for 2027 with no specific timeline, leaving significant execution uncertainty.
  • Huntington's disease is a notoriously difficult therapeutic area with multiple high-profile clinical failures across different mechanisms.
● neutral
Impact
PhasePhase 1
Time to marketEarly-stage (Phase 1). If successful through all development phases, potential approval would be several years away, likely 2029 or later.

PTC612 Updated Oct 30

What to watch

Watch for Phase 1 safety and pharmacokinetic data from PTC612, which could emerge in 2027. The more immediate value drivers for PTCT are the ST-920 BLA submission expected in Q4 2026, the PROVE-FA study of vatiquinone, and continued Sephience revenue growth. PTC612 is unlikely to be a material stock-moving catalyst for at least 12-18 months.

Bull case
  • NLRP3 inhibition is a novel anti-inflammatory mechanism with broad therapeutic potential across cardiovascular, metabolic, and neurodegenerative diseases, representing a large addressable market projected to reach ~$420 million by 2032 (62.6% CAGR).
  • PTC612 is designed to be highly potent and selective with a chemical structure distinct from other NLRP3 inhibitors, potentially offering differentiation in a competitive but early-stage field where no NLRP3 inhibitor has yet been approved.
  • PTC Therapeutics has a strong track record of advancing drugs from early development to commercialization (Sephience, Translarna, Emflaza), and the company's commercial revenue provides ample funding to develop PTC612 without dilutive financing.
Bear case
  • The NLRP3 inhibitor space is crowded with 20+ companies and 25+ drugs in development, including Roche's selnoflast (Phase 2a for coronary artery disease) and Novartis's DFV890, meaning PTC612 faces significant competition despite being early-stage.
  • PTC612 is in very early Phase 1 testing with no disclosed indication, no efficacy data, and no timeline for Phase 1 completion, making it impossible to assess its therapeutic potential or commercial viability.
  • As a small part of a diversified pipeline at a company with ~$1.3 billion in annual revenue, PTC612 is unlikely to be a material stock-moving catalyst for PTCT even if Phase 1 data are positive, and any safety signal would be a minor negative given the company's many other programs.

Other drugs in filings and trials

no drug report yet

Past FDA events & how the stock moved

2 events
DateDrugEvent1 day5 days
Jul 28, 2025SephienceApproval+10.2%+16.8%
Feb 9, 2017EmflazaApproval−3.0%+4.1%

Clinical trials

4 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
PTC923A Long-Term Safety Study of PTC923 in Participants With PhenylketonuriaPhase 3Completed247Jul 21, 2026
TranslarnaStudy of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)Phase 3Terminated · results265Feb 10, 2026
vatiquinoneA Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich AtaxiaPhase 3Completed · results146Apr 4, 2023
vatiquinoneA Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory EpilepsyPhase 3Terminated · results68Mar 18, 2023